Project Grant DP2CA301080
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$1.5M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Cancer Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
The National Cancer Institute awarded a $195,766 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Yale University for the "Synthetic Mechano-Transduction for Improved Cell Therapies in Immuno-Oncology" project. The purpose of this award is to develop an innovative approach that harnesses mechanical forces to enhance the efficacy and safety of Chimeric Antigen Receptor (CAR) T-cell therapies for solid tumors. The project aims to engineer a...
This $712,479 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) supports the development of a modular, logic-gated split chimeric antigen receptor T (CAR T) cell therapy platform for treating solid tumors. The key objectives are to: 1) Establish a split CAR T cell format that can respond to both tumor cell surface proteins...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806 in funding to develop and translate chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin for solid tumor treatment. The key products and services to be delivered include: Conducting clinical trials to evaluate the safety and efficacy of mesothelin-targeted CAR T-cell therapies, including...
This Project Grant award, totaling $1,220,394.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research Federal Grant Program (CFDA 93.395). The primary objective is to conduct a comprehensive, multi-disciplinary study exploring the molecular pathogenesis and clinical characterization of acute and chronic neurotoxicity associated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. The research plan involves investigating changes...
This $402,600 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 SNRNP200 protein for the treatment of acute myeloid leukemia (AML). The primary goals are to evaluate the efficacy and safety of anti-U5 SNRNP200 CAR T-cells, including those that secrete IL-18 to augment anti-tumor effects, in preclinical AML models. The research also aims to elucidate...
This $587,108 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to enhance the efficacy of non-activated chimeric antigen receptor (CAR) T cells for cancer treatment. The research will investigate methods to improve the transduction efficiency and functional properties of non-activated T cells by modulating type I interferon (IFN1) signaling pathways. Key objectives include: Evaluating the impact of IFN1 blockade on CAR lentivirus transduction...
This is a Project Grant award from the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The $827,942 award will fund research to investigate the role of an inhibitory receptor in regulating the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The research will have two main objectives: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic efficacy of murine...
This $285,577 project grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to Ursa Analytics, Inc., a for-profit AI and data analytics company. The grant supports the development of new unsupervised machine learning algorithms for high-throughput, label-free image analysis of chimeric antigen receptor (CAR)-T cell data. The goal is to optimize manufacturing processes for producing consistent,...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) provides $207,900.00 to The Leland Stanford Junior University to develop a three-cell synthetic immunotherapy system. The project aims to engineer T cells, natural killer (NK) cells, and macrophages to express chimeric antigen receptors (CARs) and synthetic...
This federal Project Grant award, valued at $513,859.00 and provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a persistent and continuously renewing adoptive cellular therapy platform using hematopoietic stem cell (HSC)-derived natural killer (NK) cells expressing chimeric antigen receptors (CARs). The key goals are to: (1) leverage naturally occurring NK-specific regulatory elements to drive CAR expression exclusively in NK cells, thereby...